Table 2.

Overall survival (OS) with first-line nab-P/Gem in studies of ≥45 patients with metastatic pancreatic cancer

First author, year	Type of study	Agent(s)a	n	Age, median, years	PS	Median OS (95% CI), months	P value
Von Hoff, 201110	Ph I/II	nab-Pb/Gem	67	61c	ECOG 0–1	12.2c	NR
Cartwright, 201411	Retro	nab-Pd/Gem	189	Gem-based regimens: 70	Gem-based regimens:	10.2	NR
		Gem + other chemo	1,567		KPS <70, 7%	7.0
		FOLFIRINOX	666	60	KPS <70, 1%	11.2
Santoni, 201412	Retro	nab-Pd/Gem	41	66	NR	11.6	NR
		Gem	159			5.5
		Gem + cisplatin/oxaliplatin	234			7.5
		Gem + capecitabine	43			9.1
		FOLFIRINOX	101			13.0
Krishna, 201513	Retro	nab-P/Geme	49	65	ECOG 0–1	11.1 (5.3–not reached)	NA
MPACT	Ph III	nab-P/Gem	431	62	KPS <80, ≈7%	8.7 (7.9–9.7)	<0.001
Goldstein, 20155		Gem	430	63	KPS <80, 8%	6.6 (6.0–7.2)
Giordano, 201550	Retro	nab-Pf/Gem	208	67	ECOG PS 2, 17.8%	11 (8.8–13.2)	NA
Shen, 201617	Ph II	nab-P/Gem	83	57	KPS 70–80, 30%	9.2 (5.29–7.16)	NA
Hammel, 201615	Ph II	nab-P/Gem	39	65.3	ECOG 2, 15.4%	9.2 (6.0–13.6)	NR
		nab-P + sLV5FU2	75	66.2	ECOG 2, 16.0%	11.4 (8.8–16.6)

Notes:

^anab-P at 125 mg/m² the first 3 of 4 weeks (qw 3/4) unless otherwise indicated.

^bnab-P at 100, 125, or 150 mg/m² qw 3/4.

^cFor nab-P 125 mg/m² qw 3/4 (n=44).

^dDose and schedule of nab-P not reported.

^enab-P at 125 mg/m² and Gem at 1,000 mg/m² both given q2w. Supportive care also included dexamethasone 12 mg 30 min prior to chemotherapy administration.

^Fnab-P at 100 or 125 mg/m² qw 3/4.

Abbreviations: chemo, chemotherapy; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; FOLFIRINOX, folinic acid, 5-fluorouracil, irinotecan, and oxaliplatin; Gem, gemcitabine; KPS, Karnofsky performance status; NA, not applicable; NR, not reported; nab-P, nanoparticle albumin-bound paclitaxel; Ph, phase; PS, performance status; Retro, retrospective; sLV5FU2, simplified leucovorin and 5-fluorouracil regimen.